Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash from Investing Activities (2020 - 2025)

Tarsus Pharmaceuticals has reported Cash from Investing Activities over the past 6 years, most recently at $49.3 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at $49.3 million for Q4 2025, up 182.71% from a year ago — trailing twelve months through Dec 2025 was -$42.1 million (up 78.86% YoY), and the annual figure for FY2025 was -$42.1 million, up 78.86%.
  • Cash from Investing Activities for Q4 2025 was $49.3 million at Tarsus Pharmaceuticals, up from -$4.7 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for TARS hit a ceiling of $64.1 million in Q2 2023 and a floor of -$102.2 million in Q1 2024.
  • Median Cash from Investing Activities over the past 5 years was -$168000.0 (2021), compared with a mean of -$12.3 million.
  • Biggest five-year swings in Cash from Investing Activities: crashed 47112.4% in 2022 and later surged 52634.43% in 2023.
  • Tarsus Pharmaceuticals' Cash from Investing Activities stood at -$274000.0 in 2021, then plummeted by 31731.75% to -$87.2 million in 2022, then surged by 120.47% to $17.8 million in 2023, then tumbled by 433.75% to -$59.6 million in 2024, then surged by 182.71% to $49.3 million in 2025.
  • The last three reported values for Cash from Investing Activities were $49.3 million (Q4 2025), -$4.7 million (Q3 2025), and -$51.7 million (Q2 2025) per Business Quant data.